Turku, Finland-based immunotherapy developer Faron tested its lead asset in combination with azacitidine. First and second-phase data resulted in an 85% objective response rate and a 45% complete ...
(Alliance News) - Defence Holdings PLC on Monday said it has made "material progress" in product development and partner collaboration as it moves to a new phase of expansion. Shares in the ...
Finance News; Chill Brands eyes more deals as says positioned for long-term growth; Chill Brands eyes more deals as says positioned for long-term growth ...
(Alliance News) - Ashoka WhiteOak Emerging Markets Trust PLC on Monday said it outperformed its benchmark index by 0.4% in the third quarter of 2025, as it noted a strong performance from Delta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback